1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

01 Jun 2020
Admin
News Article

Daiichi Sankyo Announces Clinical Research Collaboration To Evaluate Ds-1062 In Combination With Keytrudaa

Daiichi Sankyo Company, Limited Announced That It Has Entered Into A Clinical Trial Collaboration Agreement With A Subsidiary Of Merck &Amp; Co., Inc., Kenilworth, New Jersey, U.S.A., Known As Msd Outside The United States And Canada, To Evaluate The Combination Of Ds-1062, A Trop2 Directed Dxd Antibody Drug Conjugate (Adc), And Keytruda&Reg; (Pembrolizumab) In Patients With Previously-Treated Advanced Or Metastatic Non-Small Cell Lung Cancer (Nsclc) Without Actionable Genomic Alterations.There Are No Trop2 Directed Therapies And No Adcs Currently Approved For Treatment Of Nsclc, Which Frequently Overexpresses The Trop2 Protein.1&Ldquo;Strategic Research Collaborations Like This Support Our Goal Of Developing Our Trop2 Directed Dxd Adc In Combination With Immune Checkpoint Inhibitors To Improve Upon The Current Standard Of Care Therapies Across A Wide Range Of Nsclc Subtypes,&Rdquo; Said Gilles Gallant, Bpharm, Phd, Fopq, Senior Vice President, Global Head, Oncology Development, Oncology R&Amp;D, Daiichi Sankyo. &Ldquo;We Look Forward To Evaluating The Safety And Efficacy Of Ds-1062 In Combination With Keytruda As A Potential Combination Therapy Strategy To Advance Treatment Outcomes For Patients With Metastatic Nsclc Without Mutations Known To Drive Cancer Growth.&Rdquo;

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!